Skip to main content
Erschienen in: Metabolic Brain Disease 2/2019

03.01.2019 | Short Communication

Evaluation strategy to determine reliable demyelination in the cuprizone model

verfasst von: Uta Chrzanowski, Christoph Schmitz, Anja Horn-Bochtler, Anne Nack, Markus Kipp

Erschienen in: Metabolic Brain Disease | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

In multiple sclerosis patients, chronic clinical deficits are known to result from axonal degeneration which is triggered by inadequate remyelination. The underlying molecular mechanisms of remyelination and its failure remain currently unclear. In vivo models, among the cuprizone model, are valuable tools to study underlying mechanisms of remyelination and its failure. Since complete and reproducible demyelination of the analyzed brain region is an indispensable prerequisite for efficient remyelination experiments, in this study we systematically addressed which part of the corpus callosum is reliably and consistently demyelinated after acute cuprizone-induced demyelination. Following a novel evaluation strategy, we can show that at the level of the rostral hippocampus, the most medial sectors of the corpus callosum (spanning 500 μm in the horizontal plane) are consistently demyelinated, whereas more lateral sectors show inconsistent and incomplete demyelination. These results precisely define a part of the corpus callosum which should be used as a region of interest during remyelination experiments.
Literatur
Zurück zum Zitat Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed
Zurück zum Zitat Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol (Zurich, Switzerland) 13:329–339CrossRef Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol (Zurich, Switzerland) 13:329–339CrossRef
Metadaten
Titel
Evaluation strategy to determine reliable demyelination in the cuprizone model
verfasst von
Uta Chrzanowski
Christoph Schmitz
Anja Horn-Bochtler
Anne Nack
Markus Kipp
Publikationsdatum
03.01.2019
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 2/2019
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-018-0375-3

Weitere Artikel der Ausgabe 2/2019

Metabolic Brain Disease 2/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.